

Low lung function, sudden cardiac death and non-fatal coronary events in the general population

Suneela Zaigham ,¹ Karl-Fredrik Eriksson,² Per Wollmer,^{1,3} Gunnar Engström¹

To cite: Zaigham S, Eriksson K-F, Wollmer P, *et al.* Low lung function, sudden cardiac death and non-fatal coronary events in the general population. *BMJ Open Resp Res* 2021;**8**:e001043. doi:10.1136/bmjresp-2021-001043

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/bmjresp-2021-001043>).

Received 30 June 2021
Accepted 30 August 2021



© Author(s) or their employer(s) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Department of Clinical Sciences, Lund University, Malmö, Sweden

²Vascular Department of Angiology, Skåne University Hospital, Malmö, Sweden

³Department of Translational Medicine, Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Malmö, Sweden

Correspondence to
Dr Suneela Zaigham;
suneela.zaigham@med.lu.se

ABSTRACT

Background Many of those who suffer from a first acute coronary event (CE) die suddenly during the day of the event, most of them die outside hospital. Poor lung function is a strong predictor of future cardiac events; however, it is unknown whether the pattern of lung function impairment differs for the prediction of sudden cardiac death (SCD) versus non-fatal CEs. We examined measures of lung function in relation to future SCD and non-fatal CE in a population-based study.

Methods Baseline spirometry was assessed in 28 584 middle-aged subjects, without previous history of CE, from the Malmö Preventive Project. The cohort was followed prospectively for incidence of SCD (death on the day of a first CE, inside or outside hospital) or non-fatal CE (survived the first day). A modified version of the Lunn McNeil's competing risk method for Cox regression was used to run models for both SCD and non-fatal CE simultaneously.

Results A 1-SD reduction in forced expiratory volume in 1 s (FEV₁) was more strongly associated with SCD than non-fatal CE even after full adjustment (FEV₁: HR for SCD: 1.23 (1.15 to 1.31), HR for non-fatal CE 1.08 (1.04 to 1.13), p value for equal associations=0.002). Similar associations were found for forced vital capacity (FVC) but not FEV₁/FVC. The results remained significant even in life-long never smokers (FEV₁: HR for SCD: 1.34 (1.15 to 1.55), HR for non-fatal CE: 1.11 (1.02 to 1.21), p value for equal associations=0.038). Similar associations were seen when % predicted values of lung function measures were used.

Conclusions Low FEV₁ is associated with both SCD and non-fatal CE, but consistently more strongly associated with future SCD. Measurement with spirometry in early life could aid in the risk stratification of future SCD. The results support the use of spirometry for a global assessment of cardiovascular risk.

INTRODUCTION

Sudden cardiac death (SCD) is an unexpected death of cardiac origin, occurring within 1 hour of onset of symptoms in witnessed cases or within 24 hours of being seen alive and well if unwitnessed.¹ Since there is usually incomplete information from witnesses in population-based settings, other operational definitions are frequently used, such as coronary deaths outside hospital or a fatal outcome during the day of the acute coronary

KEY MESSAGES

- ⇒ Although poor lung function is a strong predictor of future cardiac events, it is unknown whether sudden cardiac death events or coronary events that survive the first 24 hours are more strongly associated with poor lung function earlier in life.
- ⇒ Low forced expiratory volume in 1 s is more strongly associated with future sudden cardiac death than incident coronary events that survive the first day, even in life-long never smokers.
- ⇒ More specific markers of predicting sudden cardiac death (SCD) in the general population are needed as a large proportion of the absolute number of sudden cardiac death comes from those not considered to be high risk; we propose measurement with spirometry in early life could aid in the risk stratification of future SCD.

event (CE) in individuals without any previous history of acute CEs. The typical pathophysiological sequence of events in the majority of cases is the onset of ventricular tachycardia, degenerating into ventricular fibrillation and finally to asystole.² Coronary heart disease (CHD) is the underlying condition in approximately 70%–80% of SCD events,^{1,3,4} and in many cases, SCD is the first and only indication of heart disease.⁵ It has been thought of as an ‘epidemiological paradox’ since a large proportion of the absolute number of SCD comes from those not considered to be high-risk individuals.^{4,6} The value of conventional cardiovascular risk markers to predict fatal arrhythmic events in individual subjects is low, and, therefore, a search for more specific markers of predicting fatal arrhythmias leading to SCD are needed.² Although an association between low vital capacity (VC) and SCD has been proposed,^{7,8} there have not been many studies of the general population to explore this association further. Chronic obstructive pulmonary disease (COPD) has been associated with SCD,⁹ but few studies exist for pulmonary function in otherwise healthy individuals, as a marker of SCD. A



prospective population-based study in 2015 assessed impaired pulmonary function as a risk predictor for SCD in over 1000 middle-aged men and found that reduced lung function as measured by spirometry was a robust predictor of SCD; a finding that was also replicated in non-smokers.¹⁰ In an additional population-based study in Malmö, Sweden, it was found that in just under 5500 apparently healthy men with moderately reduced lung function, a higher case-fatality was found for future CE.¹¹ One of the most striking findings was that lung function predicted the fatality of a CE when the men were comparatively young (mean age 47 years) and healthy, that is, many years before the CE took place itself.

Although poor lung function is a strong predictor of future cardiac events, it is unknown whether the pattern of lung function impairment differs for the prediction of SCD versus non-fatal CE, and which of the two outcomes are more strongly associated with poor lung function earlier in life.

In this study, we aim to assess if measures of spirometry are associated with future SCD and non-fatal CE using prospective data from a general population study in over 28 500 participants.

METHODS

Study population

The study population consisted of subjects from the Malmö Preventive Project where middle-aged individuals were screened with an aim to offer preventative treatment to any identified high-risk individuals. Screening was carried out between 1974 and 1992 in 33 346 subjects (22 444 men and 10 902 women) (participation rate of over 70%). Complete birth cohorts for 1921–1949 were invited for a physical examination, laboratory tests, spirometry and self-administered questionnaires. Men were mostly screened between 1974 and 1982 and women between 1982 and 1992. The screening programme was approved and funded by the Health Service Authority of Malmö.

Subjects with prevalent CHD or cardiovascular disease (CVD) were excluded, which included a history of CEs or a history of stroke, based on self-reported questionnaire data or registers of hospital inpatients (n=182). Spirometry was performed in birth cohorts during most but not all screening periods (94% of men and 71% of women); however, individuals were not selected based on symptoms or disease. Subjects with missing information on spirometry were excluded (n=4389). Subjects with missing information on key covariates were excluded (n=147). Subjects with an erythrocyte sedimentation rate (ESR) ≥ 50 mm/hour were excluded as this could potentially indicate the presence of a specific inflammatory lung pathology (n=63). The final study population consisted of 28 584 subjects (20 939 men and 7645 women).

Patient and public involvement

Study participants were not involved in the study design and conduct, or the reporting and dissemination of the study findings.

Baseline examinations

Forced expiratory volume in 1 s (FEV₁) and forced VC (FVC) were measured using a spirotion apparatus (Drägerwerk AG, Lübeck, Germany), carried out by trained nursing staff. Only one acceptable manoeuvre was required. FEV₁, FVC and FEV₁/FVC were standardised for age and height using published equations derived from linear regression of never smokers in the present cohort^{12 13} (online supplemental methods). Height (metres) was measured using a fixed stadiometer; weight (kg) was measured on a balance beam scale. Body mass index (BMI) was calculated as kg/m². Blood pressure (BP) (mm Hg) was measured after a 10 min rest in the supine position (two measurements taken and mean value recorded). Blood samples were taken after an overnight fast and analysed at the Department of Clinical Chemistry, Malmö University hospital. ESR was determined according to the Westergren method. Information on smoking habits was assessed using a questionnaire, and based on their responses, participants were divided into current, former or never smokers.

Endpoint ascertainment

All individuals with a history of CE, according to self-report or patient registers, were excluded. SCD was defined as a fatal CE where death took place on the first day of the CE (within the first 24 hours), in individuals without a previous CE. This includes cases that died out of hospital. International Classification of Diseases (ICD) 8 and 9 codes included 410, 412 and 414; and ICD 10 codes I21, I24 and I25 were used.^{14 15} Cause of death was based on autopsy for 61% of the SCDs in this study. A non-fatal CE was defined as a CE with ICD 8 and 9 code 410 or ICD 10 code I21, which survived the first day. Data linkage with the National Cause of Death Registry, Swedish Hospital Discharge registry and the Malmö Myocardial Infarction Register¹⁶ was used to retrieve cases. All subjects were followed from the baseline examinations until the first non-fatal CE or fatal CE, death from other causes, emigration or last follow-up date (31 December 2018), whichever came first. During the entire follow-up period, the Swedish inpatient registry had been in operation in the south of Sweden, which became nationwide in 1987. Data from this registry have acceptable validity for epidemiological research.¹⁷

Statistical analysis

All analyses were carried out using SPSS V.26 (IBM, Armonk, New York, USA) and Stata V.14.0. Cox regression models were run to obtain HRs for SCD and non-fatal CE per 1-SD change in lung function measures. Time from baseline examination to the first incident CE, SCD, emigration or mortality from other causes, whichever came first, was used. Adjustments were made for potential confounding factors (model 1: age, sex and height; model 2: age, sex, height, BMI, smoking status, prevalent diabetes, systolic BP and cholesterol). Time-dependent

Table 1 Baseline characteristics (n=28 584)

Demographic characteristic	
Age (years)	44.6 (±7.2)
Gender (% , male)	73.3
Height (m)	1.74 (±0.09)
BMI (kg/m ²)	24.4 (±3.5)
Smoking status (%)	
Current smokers	48.1
Former smokers	17.1
Never smokers	34.8
Prevalent diabetes (%)	3.1
Prevalent COPD (%)	0.3
Cholesterol (mmol/L)	5.61 (±1.07)
ESR (mm/h)*	5.0 (3.0–8.0)
Systolic BP (mm Hg)	126 (±15)
Lung function measurement	
FEV ₁ (L)	3.28 (±0.82)
FEV ₁ (%predicted)	95.2 (±17.9)
FVC (L)	4.20 (±1.01)
FVC (%predicted)	97.0 (±16.5)
FEV ₁ /FVC	0.785 (±0.092)
FEV ₁ /FVC (%predicted)	98.5 (11.4)
Data are presented as mean±SD unless otherwise stated. *Median values with 25th–75th percentiles for covariates with skewed distribution.	
BMI, body mass index; BP, blood pressure; COPD, chronic obstructive pulmonary disease; ESR, erythrocyte sedimentation rate; FEV ₁ , forced expiratory volume in 1 s; FVC, forced vital capacity.	

covariate analysis was used to check proportional hazards assumption for all models. They were met for all except models for non-fatal outcomes per 1-SD decrease in FEV₁,

FEV₁/FVC ratio and FVC (for FVC model 1 only). To further assess the proportional hazards for these models, we tested the assumptions using Kaplan Meier plots.

A modified version of the Lunn McNeil's competing risks method for Cox regression¹⁸ was used to run models for both SCD and non-fatal CE simultaneously. The null hypothesis associated with the p value obtained from this method is that the lung function variable has the same association with SCD and non-fatal CE. This method has been described in detail elsewhere.¹⁹ In order to assess the effect of inflammation, models were additionally adjusted for ESR. To fully control for the effect of smoking, we carried out an analysis in life long never smokers (n=9947).

RESULTS

Subject characteristics are presented in [table 1](#). The mean age of participants was approximately 45 years. Almost half the cohort were current smokers; however, the known prevalence of COPD at baseline was low at 0.3%. Mean follow-up time was approximately 30 years.

Sudden cardiac death

There were 1609 SCD events over the follow-up period. Crude incident rates of SCD by quartiles of lung function measures are presented in [table 2](#) and online supplemental figure 1. Q1 (low lung function) had the highest rates of SCD (events per 1000 person-years). There was an increased adjusted risk of SCD per 1-SD decrease in FEV₁ and FVC (L) ([table 3](#)), which remained significant after additionally adjusting for ESR (HR per 1-SD decrease in FEV₁ and FVC (L): (1.21 (1.13 to 1.30) and 1.19 (1.11–1.28), respectively. Similar associations were seen using %predicted values of FEV₁ and FVC (online supplemental table 1).

Table 2 Incident SCD and non-fatal CE by quartiles of lung function (n=28 584)

	Q1	Q2	Q3	Q4
FEV ₁ (L)	≤2.70	2.80–3.20	3.30–3.80	≥3.90
Subjects (n=28 584)	7454	6691	7584	6855
SCD events n (n per 1000 person-years)	518 (2.6)	405 (2.0)	405 (1.7)	281 (1.2)
Non-fatal CE n (n per 1000 person-years)	1093 (5.4)	994 (5.0)	1089 (4.6)	826 (3.6)
FVC (L)	≤3.40	3.50–4.10	4.20–4.80	≥4.90
Subjects (n=28 584)	6950	6828	7283	7523
SCD events n (n per 1000 person-years)	435 (2.3)	414 (2.1)	424 (1.9)	336 (1.4)
Non-fatal CE n (n per 1000 person-years)	959 (5.0)	1017 (5.0)	1084 (4.8)	942 (3.8)
FEV ₁ /FVC	≤0.730	0.730–0.787	0.788–0.843	≥0.844
Subjects (n=28 584)	7155	7178	7130	7121
SCD events n (n per 1000 person-years)	508 (2.5)	397 (1.8)	358 (1.6)	346 (1.6)
Non-fatal CE n (n per 1000 person-years)	1089 (5.4)	1019 (4.6)	1020 (4.6)	874 (3.9)
CE, coronary events; FEV ₁ , forced expiratory volume in 1 s; FVC, forced vital capacity; Q, quartile; SCD, sudden cardiac death.				

**Table 3** HRs for fatal (death on day 1) and non-fatal CEs per 1-SD decrease in lung function measures (n=28 584)

		Fatal coronary events (SCD) (n=1609)	Non-fatal coronary events (n=4002)	P value*
FEV ₁	Model 1	1.41 (1.33 to 1.51)	1.20 (1.15 to 1.25)	<0.0001
	Model 2	1.23 (1.15 to 1.31)	1.08 (1.04 to 1.13)	0.0020
FVC	Model 1	1.41 (1.32 to 1.51)	1.19 (1.14 to 1.24)	0.0001
	Model 2	1.21 (1.13 to 1.30)	1.08 (1.03 to 1.13)	0.0055
FEV ₁ /FVC	Model 1	1.07 (1.02 to 1.13)	1.05 (1.01 to 1.08)	0.3947
	Model 2	1.05 (1.00 to 1.10)	1.02 (0.99 to 1.06)	0.4257

Model 1: age, sex, height.

Model 2: age, sex, height, BMI, smoking status, prevalent diabetes, systolic BP, cholesterol.

*Null hypothesis: lung function measure has the same association with incident fatal coronary events and incident non-fatal coronary events. BMI, body mass index; BP, blood pressure; CE, coronary event; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; SCD, sudden cardiac death.

In life-long never smokers (table 4 and online supplemental table 2), there was a strong-adjusted risk of SCD per 1-SD decrease in FEV₁ and FVC (L) (HR: 1.34 (1.15 to 1.55)) and 1.36 (1.16 to 1.59), respectively) and per 1-SD decrease in %predicted FEV₁ and FVC (HR: 1.23 (1.11 to 1.36) and 1.24 (1.12 to 1.38), respectively). After additionally adjusting for ESR in never smokers, results remained largely unchanged (results not shown).

Incident non-fatal CE

There were 4002 non-fatal CE during the follow-up period. Individuals with low lung function (Q1) had the highest rates of non-fatal CE (table 2, online supplemental figure 2). HR of non-fatal CE per 1-SD decrease in spirometry measures is shown in table 3. There was an increased adjusted risk of non-fatal CE per 1-SD decrease in FEV₁ and FVC (L), which remained significant after additionally adjusting for ESR (HR per 1-SD decrease in FEV₁ and FVC (L): 1.07 (1.02 to 1.12) and 1.06 (1.02 to 1.11), respectively. Similar associations were seen using %predicted values of FEV₁ and FVC (online supplemental table 1).

In life long never smokers (table 4), there was a strong adjusted risk of non-fatal CE per 1-SD decrease in FEV₁

and FVC (L) (HR: 1.11 (1.02 to 1.21)) and 1.16 (1.05 to 1.27), respectively) and per 1-SD decrease in %predicted FEV₁ and FVC (HR: 1.08 (1.02 to 1.15) and 1.10 (1.03 to 1.17), respectively, online supplemental table 2). After additionally adjusting for ESR in never smokers, results remained largely unchanged (results not shown).

Comparing the risk of SCD events and incident non-fatal CE for baseline lung function

An 1-SD reduction in FEV₁ and FVC was more strongly associated with SCD than non-fatal CE even after full adjustment (p value 0.0020 and 0.0055, respectively) (table 3), which remained significant even after further adjusting for ESR. Similar associations were seen using %predicted values of FEV₁ and FVC (online supplemental table 1). In life-long never smokers, a 1-SD reduction in FEV₁ remained more strongly associated with SCD than non-fatal CE (p value, 0.0380), which after further adjustment for ESR was borderline significant (p value, 0.05). Similar associations were seen using %predicted values of FEV₁ and FVC (online supplemental table 2), and after further adjustment for ESR, results remained borderline significant for FEV₁ %predicted (p value for equal associations—0.045).

Table 4 Analysis in never smokers: HRs for fatal (death on day 1) and non-fatal coronary events per 1-SD decrease in lung function measures (n=9947)

		Fatal coronary events (SCD) (n=364)	Non-fatal coronary events (n=1064)	P value*
FEV ₁	Model 1	1.44 (1.24 to 1.66)	1.17 (1.07 to 1.27)	0.0162
	Model 2	1.34 (1.15 to 1.55)	1.11 (1.02 to 1.21)	0.0380
FVC	Model 1	1.48 (1.26 to 1.72)	1.22 (1.11 to 1.33)	0.0369
	Model 2	1.36 (1.16 to 1.59)	1.16 (1.05 to 1.27)	0.0880
FEV ₁ /FVC	Model 1	1.01 (0.92 to 1.13)	0.99 (0.93 to 1.05)	0.6462
	Model 2	1.02 (0.92 to 1.12)	0.98 (0.93 to 1.05)	0.6160

Model 1: age, sex, height.

Model 2: age, sex, height, BMI, prevalent diabetes, systolic BP, cholesterol.

*Null hypothesis: lung function measure has the same association with incident fatal coronary events and incident non-fatal coronary events. BMI, body mass index; BP, blood pressure; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; SCD, sudden cardiac death.




Figure 1 Age, sex and height adjusted HRs of fatal coronary events (SCD: death on day of coronary event) and incident non-fatal coronary events by quartiles of FEV₁ (L) in subjects with no known prevalent cardiovascular disease. Q4 is the reference group (highest lung function). Results based on 28 584 individuals, 4002 non-fatal CHD and 1609 fatal coronary events (SCD). FEV₁, forced expiratory volume in 1; SCD, sudden cardiac death.

An additional analysis in ever smokers (former and current smokers) showed broadly similar results to the main analysis, where FEV₁ and FVC (litres and %predicted values) were more strongly associated with SCD than non-fatal CE, even after full adjustments (online supplemental table 3), which remained largely unchanged after taking into account ESR (results not shown).

Figure 1 shows age, sex and height-adjusted HR of SCD and non-fatal CE by quartiles of FEV₁ (L).

DISCUSSION

This prospective study shows that poor lung function is more strongly associated with SCD events than non-fatal CE in the general population, even in life-long never smokers.

The present study is the first to compare the HR of SCD directly to those of non-fatal CE in relation to various baseline lung function measures in the healthy general population. A study assessing risk factors for SCD in under 7000 middle-aged British men found that FEV₁ was not independently associated with SCD after 8 years of follow-up.²⁰ The reason for this difference in results is unclear; however, the present study comprised of a much larger cohort of subjects over a longer follow-up period, which may be more reflective of the life-time risk of SCD in relation to early lung function.

A strong association exists between COPD and CVD, where CVD morbidity and mortality are known to be more frequent in patients with COPD than in the general population.²¹ It has been found that COPD is also associated with an increased risk of SCD.⁹ The prevalence of COPD in the present cohort was very low at baseline. The FEV₁/FVC ratio at baseline was not associated with future SCD, and an association between FEV₁ and SCD was replicated in life-long never smokers. This suggests that the association between poor lung function and SCD extends beyond that expected due to the known link between COPD and CVD. Our findings support liberal use of spirometry in general health assessments.

For those with low lung function, lifestyle changes to improve lung health should be implemented to prevent further deterioration of lung function and increase in cardiac risk. There is also reason to evaluate the levels of the most important cardiovascular risk factors in those with low lung function and optimise their treatment to further reduce the risk of SCD and non-fatal CE.

It has been found that left ventricular (LV) dysfunction is associated with an increased risk of SCD²² along with being associated with low FEV₁ and FVC.²³ However, a reduced FVC has been associated with cardiac hospitalisations even after adjustments for left heart size and in those with normal LV ejection fraction (LVEF).²³ Previous research nevertheless found that different patterns of loss of lung health in young adulthood are associated with specific cardiac phenotypes in middle age.²⁴ A decline in FVC with a preserved FEV₁/FVC ratio was found to be associated with LV hypertrophy and diastolic dysfunction—a ‘hypertrophic, high output phenotype’ later in life, whereas a declining FEV₁ with decline in FEV₁/FVC was associated with decreased left heart chamber size and decreased cardiac output—a ‘small heart, low output phenotype’.²⁴ There was no echocardiography information available in the present study, so we were unable to assess the role of subclinical heart failure in the relationship between low lung function and SCD. If this association is explained to some extent by the presence of heart failure, it would then be important to establish if it is independent of LVEF by assessing whether similar findings between reduced lung function and ventricular arrhythmias (VA) or SCD are also observed in those with diastolic dysfunction.

There is emerging evidence that arrhythmias contribute to the increased cardiovascular mortality in COPD.²⁵ However, the pathophysiology that links COPD to fatal arrhythmias may indeed differ from that which links low lung function in the absence of pulmonary disease to fatal malignant arrhythmias. A study in the ‘Men Born in 1914’ cohort in Malmö, Sweden assessed the association between low levels of lung function and the occurrence and prognostic significance of VA.²⁶ In 68-year-old men free from CVD, the occurrence of VA on 24-hour ambulatory ECG (24-hour ECG) was inversely associated with pulmonary function, and additionally the increased cardiac risk and mortality risk associated with VA were mainly limited to men with low FEV₁ %predicted or low FEV₁/VC. The Cardiovascular Health Study also used 24-hour ECG to assess the prevalence and correlates of cardiac arrhythmias in the elderly and reported significantly lower lung function in those with arrhythmias compared with those without.²⁷ These studies support the hypothesis of VA as a potential link between lung function and SCD. To better understand underlying mechanisms, further studies are needed of the arrhythmic risk in individuals with poor lung function.

A corrected QT interval (QTc) of >440 ms is associated with a high risk of SCD, independently of age, sex, history of myocardial infarction, heart rate and medication use.²⁸



The population-based Multi-Ethnic Study of Atherosclerosis found an inverse association between FEV₁%, FVC%, FEV₁/FVC% and prolonged QTc.²⁹ The results suggest that low lung function could be a risk factor for longer QTc in the general male population, even in those without lung disease. Autonomic dysfunction associated with reduced lung function has been suggested as a potential mechanism for these findings.²⁹ We did not have ECG information in the present study, so were unable to determine if the association between low lung function and SCD was explained by a prolonged cardiac repolarisation.

An additional explanation may include the association between lung function and atherosclerosis,³⁰ which could be mediated through systemic inflammation and potentially increase the risk of VA and SCD. Although we attempt to take into the account the role of systemic inflammation by additionally adjusting the final models for ESR, we are aware that there is likely a residual effect of confounding from inflammation that could potentially effect the results. However, it is unlikely that any residual confounding effect influenced the results of SCD more than non-fatal outcomes; therefore, it cannot explain the stronger association of low lung function with SCD compared with non-fatal CE.

Limitations

The study protocol was developed before the current guidelines for spirometry were developed. Therefore, no nose clips were used, and only one acceptable manoeuvre was required. All lung function measurements were prebronchodilator values. However, it has been thought that postbronchodilator measurements may not be necessary in studies assessing long-term outcomes.³¹ Due to the long follow-up time associated with prospective follow-up studies, there are many risk factors that would have changed over this period, such as smoking status, BMI, diagnosis of COPD/other comorbidities or the use of medications such as inhaled corticosteroids. However, we do not expect that the results were influenced by an increase in uptake of smoking over the follow-up period as prevalence of smoking in Sweden decreased over the duration of the study³² and is uncommon for non-smokers to start smoking in adulthood.³³ Changing smoking habits should affect the risk of SCD and non-fatal CE in a similar way, and a systematic bias seems unlikely. It has been found that the burden of CVD in 50-year old men in Sweden has reduced over the last approximately 50 years,³⁴ and although we expect this would be mirrored in the population of Malmö, it would if anything bias results towards the null.

It has generally been established that a greater proportion of the out-of-hospital deaths is directly caused by ventricular dysrhythmia rather than coronary thrombosis³⁵ and FEV₁ could be a potentially useful tool in risk stratification for out of hospital SCD in the general population.³⁶ We were unable to determine whether

the fatal CEs were witnessed and, therefore, whether death occurred within the first hour of onset of symptoms. However, we are able to select cases of fatal CE that occurred on the day of an acute CE, which, therefore, fulfils the definition of unwitnessed SCD events and would also include both in and out of hospital SCD.

SCD is a devastating event with profound consequences for surviving family members.¹ Prediction of SCD in the general population remains a challenge as the largest patient groups for SCD are those with the fewest known risk factors.^{4,37} This study is the first to directly compare the risk of SCD and non-fatal CE in the general population in relation to baseline lung function measures in both men and women.

CONCLUSION

Low FEV₁ is consistently more strongly associated with future SCD than incident non-fatal CE. Measurement with spirometry in early life could aid in the risk stratification of future SCDs, and, therefore, allow for early intervention to potentially reduce the risk of this devastating event.

Contributors SZ, K-FE, PW and GE participated in study design, interpretation of data, drafting the manuscript and approved the final version of the manuscript. SZ performed the statistical analyses and prepared the first draft of the manuscript. All authors take responsibility for the integrity and accuracy of the work. The authors read and approved the final manuscript.

Funding This study was supported by the Swedish Heart-Lung foundation [2016–0315]. The funding body had no role in the study design or interpretation of the results.

Competing interests PW reports grants from Swedish Heart and Lung Foundation during the conduct of the study, and personal fees from Chiesi Pharma, personal fees from GlaxoSmithKline, outside the submitted work. PW has a patent device and method for pulmonary function measurement issued.

Patient consent for publication Not required.

Ethics approval The Health Service Authority of Malmö approved and funded the screening programme. Linkage with the national cause of death and patient registers and ethical approval to study incidence of cardiopulmonary diseases and death was approved by the Regional Ethics Committee at Lund University (LU 85-2004; LU 2011-412).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. The MPP steering committee coordinates research using the MPP database. The data base is open for applications for research projects. Contact: Anders Dahlin, PhD, data manager, Email: Anders.Dahlin@med.lu.se.

Author note The abstract from this manuscript has been presented as an e-poster at the European Respiratory Society (ERS) International Congress 2021.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

 Suneela Zaigham <http://orcid.org/0000-0002-9132-5665>

REFERENCES

- 1 Adabag AS, Luepker RV, Roger VL, *et al.* Sudden cardiac death: epidemiology and risk factors. *Nat Rev Cardiol* 2010;7:216–25.
- 2 Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. *N Engl J Med Overseas Ed* 2001;345:1473–82.
- 3 Wong CX, Brown A, Lau DH, *et al.* Epidemiology of sudden cardiac death: global and regional perspectives. *Heart Lung Circ* 2019;28:6–14.
- 4 Myerburg RJ, Junttila MJ. Sudden cardiac death caused by coronary heart disease. *Circulation* 2012;125:1043–52.
- 5 Zheng ZJ, Croft JB, Giles WH, *et al.* Sudden cardiac death in the United States, 1989 to 1998. *Circulation* 2001;104:2158–63.
- 6 Srinivasan NT, Schilling RJ. Sudden cardiac death and arrhythmias. *Arrhythm Electrophysiol Rev* 2018;7:111–7.
- 7 Friedman GD, Klatsky AL, Siegelau AB. Lung function and risk of myocardial infarction and sudden cardiac death. *N Engl J Med* 1976;294:1071–5.
- 8 Kannel WB, Schatzkin A. Sudden death: lessons from subsets in population studies. *J Am Coll Cardiol* 1985;5:141B–9.
- 9 van den Berg ME, Stricker BH, Brusselle GG, *et al.* Chronic obstructive pulmonary disease and sudden cardiac death: a systematic review. *Trends Cardiovasc Med* 2016;26:606–13.
- 10 Kurl S, Jae SY, Kauhanen J, *et al.* Impaired pulmonary function is a risk predictor for sudden cardiac death in men. *Ann Med* 2015;47:381–5.
- 11 Engström G, Hedblad B, Janzon L. Reduced lung function predicts increased fatality in future cardiac events. A population-based study. *J Intern Med* 2006;260:560–7.
- 12 Zaigham S, Nilsson PM, Wollmer P, *et al.* The temporal relationship between poor lung function and the risk of diabetes. *BMC Pulm Med* 2016;16:75.
- 13 Söderholm M, Zia E, Hedblad B, *et al.* Lung function as a risk factor for subarachnoid hemorrhage: a prospective cohort study. *Stroke* 2012;43:2598–603.
- 14 Rapola JM, Virtamo J, Korhonen P, *et al.* Validity of diagnoses of major coronary events in national registers of hospital diagnoses and deaths in Finland. *Eur J Epidemiol* 1997;13:133–8.
- 15 Engström G, Hedblad B, Stavenow L, *et al.* Fatality of future coronary events is related to inflammation-sensitive plasma proteins. *Circulation* 2004;110:27–31.
- 16 Engstrom G, Berglund G, Goransson M, *et al.* Distribution and determinants of ischaemic heart disease in an urban population. A study from the myocardial infarction register in Malmo, Sweden. *J Intern Med* 2000;247:588–96.
- 17 Ludvigsson JF, Andersson E, Ekblom A, *et al.* External review and validation of the Swedish national inpatient register. *BMC Public Health* 2011;11:450.
- 18 Lunn M, McNeil D. Applying COX regression to competing risks. *Biometrics* 1995;51:524–32.
- 19 Zaigham S, Johnson L, Wollmer P, *et al.* Measures of low lung function and the prediction of incident COPD events and acute coronary events. *Respir Med* 2018;144:68–73.
- 20 Wannamethee G, Shaper AG, Macfarlane PW, *et al.* Risk factors for sudden cardiac death in middle-aged British men. *Circulation* 1995;91:1749–56.
- 21 Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. *Chest* 2005;128:2640–6.
- 22 Lane RE, Cowie MR, Chow AWC. Prediction and prevention of sudden cardiac death in heart failure. *Heart* 2005;91:674–80.
- 23 Burroughs Peña MS, Dunning A, Schulte PJ, *et al.* Pulmonary function and adverse cardiovascular outcomes: can cardiac function explain the link? *Respir Med* 2016;121:4–12.
- 24 Cuttica MJ, Colangelo LA, Shah SJ, *et al.* Loss of lung health from young adulthood and cardiac phenotypes in middle age. *Am J Respir Crit Care Med* 2015;192:76–85.
- 25 Konecny T, Somers KR, Park JY, *et al.* Chronic obstructive pulmonary disease as a risk factor for ventricular arrhythmias independent of left ventricular function. *Heart Rhythm* 2018;15:832–8.
- 26 Engström G, Wollmer P, Hedblad B, *et al.* Occurrence and prognostic significance of ventricular arrhythmia is related to pulmonary function: a study from "men born in 1914," Malmö, Sweden. *Circulation* 2001;103:3086–91.
- 27 Manolio TA, Furberg CD, Rautaharju PM, *et al.* Cardiac arrhythmias on 24-h ambulatory electrocardiography in older women and men: the cardiovascular health study. *J Am Coll Cardiol* 1994;23:916–25.
- 28 Straus SMJM, Kors JA, De Bruin ML, *et al.* Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. *J Am Coll Cardiol* 2006;47:362–7.
- 29 Armstrong HF, Lovasi GS, Soliman EZ, *et al.* Lung function, percent emphysema, and QT duration: the multi-ethnic study of atherosclerosis (MESA) lung study. *Respir Med* 2017;123:1–7.
- 30 Zureik M, Kauffmann F, Touboul PJ, *et al.* Association between peak expiratory flow and the development of carotid atherosclerotic plaques. *Arch Intern Med* 2001;161:1669–76.
- 31 Mannino DM, Diaz-Guzman E, Buist S. Pre- and post-bronchodilator lung function as predictors of mortality in the lung health study. *Respir Res* 2011;12:136.
- 32 Midlöv P, Calling S, Sundquist J, *et al.* The longitudinal age and birth cohort trends of smoking in Sweden: a 24-year follow-up study. *Int J Public Health* 2014;59:243–50.
- 33 Elders MJ, Perry CL, Eriksen MP, *et al.* The report of the surgeon General: preventing tobacco use among young people. *Am J Public Health* 1994;84:543–7.
- 34 Zhong Y, Rosengren A, Fu M, *et al.* Secular changes in cardiovascular risk factors in Swedish 50-year-old men over a 50-year period: the study of men born in 1913, 1923, 1933, 1943, 1953 and 1963. *Eur J Prev Cardiol* 2017;24:612–20.
- 35 Michalodimitrakis M, Mavroforou A, Giannoukas AD. Lessons learnt from the autopsies of 445 cases of sudden cardiac death in adults. *Coron Artery Dis* 2005;16:385–9.
- 36 Kurl S, Jae SY, Laukkanen JA. Reduced lung function and the risk of out-of-hospital sudden cardiac death. *Eur Respir J* 2014;44:1355–7.
- 37 Mehra R. Global public health problem of sudden cardiac death. *J Electrocardiol* 2007;40:S118–22.

ONLINE SUPPLEMENTS

Title: Low lung function, sudden cardiac death and non-fatal coronary events in the general population

- Supplemental methods
- Supplement Figure 1
- Supplement Figure 2
- Supplement Table 1
- Supplement Table 2
- Supplement Table 3

Supplemental methods

Men:

Predicted FEV1 (L): $4.422 \times \text{height (m)} - 0.0381 \times \text{age (years)} - 2.483$

Pred. FVC (L): $6.58 \times \text{height} - 0.033 \times \text{age} - 5.54$


Pred. FEV1/FVC: $1.156 - 0.1556 \times \text{height} - 0.002025 \times \text{age}$

Women:


Pred. FEV1 (L): $3.615 \times \text{height} - 0.0217 \times \text{age} - 2.134$

Pred. FVC (L): $4.866 \times \text{height} - 0.020 \times \text{age} - 3.644$

Pred. FEV1/FVC: $1.032 - 0.079 \times \text{height} - 0.002 \times \text{age}$



Supplement Figure 1: Kaplan Meier survival curves of SCD by quartiles of FEV₁ (L). Q1: lowest FEV₁, Q4: highest FEV₁.



Supplement Figure 2: Kaplan Meier survival curves of non-fatal CE by quartiles of FEV₁ (L). Q1: lowest FEV₁, Q4: highest FEV₁.

Supplement Table 1:

Hazard ratios for fatal (death on day 1) and non-fatal coronary events per 1 SD decrease in %predicted lung function measures (n= 28 584)

		Fatal coronary events (SCD) (n=1609)	Non-fatal coronary event (n=4002)	p-value*
FEV ₁ (%predicted)	Model 1	1.30 (1.24-1.36)	1.15 (1.11-1.18)	<0.0001
	Model 2	1.17 (1.11-1.23)	1.06 (1.03-1.10)	0.0011
FVC(%predicted)	Model 1	1.28 (1.22-1.35)	1.13 (1.10-1.17)	<0.0001
	Model 2	1.15 (1.10-1.21)	1.05 (1.02-1.08)	0.0024
FEV ₁ /FVC(%predicted)	Model 1	1.07 (1.02-1.12)	1.05 (1.02-1.08)	0.4152
	Model 2	1.05 (1.00-1.10)	1.02 (0.99-1.05)	0.4409

Model 1: age, sex, height

Model 2: age, sex, height, BMI, smoking status, prevalent diabetes, systolic BP, cholesterol.

*Null hypothesis: lung function measure has the same association with incident fatal coronary events and incident non-fatal coronary events

Supplement Table 2:

Analysis in never-smokers: Hazard ratios for fatal (death on day 1) and non-fatal coronary events per 1 SD decrease in %predicted lung function measures (n=9947)

		Fatal coronary events (SCD) (n=364)	Non-fatal coronary event (n=1064)	p-value*
FEV ₁ (%predicted)	Model 1	1.29 (1.17-1.42)	1.12 (1.06-1.19)	0.0145
	Model 2	1.23 (1.11-1.36)	1.08 (1.02-1.15)	0.0324
FVC(%predicted)	Model 1	1.31 (1.19-1.45)	1.14 (1.07-1.21)	0.0154
	Model 2	1.24 (1.12-1.38)	1.10 (1.03-1.17)	0.0391
FEV ₁ /FVC(%predicted)	Model 1	1.01 (0.92-1.12)	0.99 (0.93-1.05)	0.6569
	Model 2	1.02 (0.92-1.12)	0.99 (0.93-1.12)	0.6230

Model 1: age, sex, height

Model 2: age, sex, height, BMI, prevalent diabetes, systolic BP, cholesterol.

*Null hypothesis: lung function measure has the same association with incident fatal coronary events and incident non-fatal coronary events

Supplement Table 3:

Analysis in ever-smokers (former and current): Hazard ratios for fatal (death on day 1) and non-fatal coronary events per 1 SD decrease in lung function measures (litres and %predicted) (n=18,637)

		Fatal coronary events (SCD) (n=1245)	Non-fatal coronary event (n=2938)	p-value*
FEV ₁ (L)	Model 1	1.32 (1.23-1.42)	1.14 (1.09-1.20)	0.0012
	Model 2	1.29 (1.20-1.38)	1.12 (1.07-1.18)	0.0022
FVC (L)	Model 1	1.33 (1.23-1.44)	1.14 (1.08-1.20)	0.0008
	Model 2	1.27 (1.18-1.37)	1.10 (1.05-1.16)	0.0027
FEV ₁ /FVC	Model 1	1.05 (0.99-1.11)	1.03 (1.00-1.07)	0.6377
	Model 2	1.07 (1.01-1.13)	1.04 (1.01-1.08)	0.4991
FEV ₁ (%predicted)	Model 1	1.25 (1.18-1.32)	1.11 (1.07-1.15)	0.0007
	Model 2	1.22 (1.16-1.29)	1.09 (1.06-1.14)	0.0012
FVC(%predicted)	Model 1	1.24 (1.17-1.31)	1.10 (1.06-1.14)	0.0006
	Model 2	1.19 (1.13-1.26)	1.07 (1.04-1.11)	0.0018
FEV ₁ /FVC(%predicted)	Model 1	1.05 (0.99-1.11)	1.03 (1.00-1.07)	0.6566
	Model 2	1.07 (1.01-1.13)	1.04 (1.01-1.08)	0.5156

Model 1: age, sex, height

Model 2: age, sex, height, BMI, prevalent diabetes, systolic BP, cholesterol.

*Null hypothesis: lung function measure has the same association with incident fatal coronary events and incident non-fatal coronary events